Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact

Isin US62855J1043
Ticker MYGN
Currency $
Aware Investor Index (AII) 0.1202
Recommendation HOLD
P/E 33.39
ROE 13.25 %
Capitalization 3,310,852,000 $
Dividend Yield 0.00 %
P/S 4.39
AII Position 465
P/E Position 447
ROE Position 309
Capitalization Position 647
Dividend Yield Position 629
Sales 753,800,000 $
10-Year Average Earnings 99,152,600 $
Shares Outstanding 72,400,000
Equity 748,100,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
MYRIAD GENETICS Investor Relations Web Site http://investor.myriad.com


2016 6 753,800,000.00 $
2015 6 723,100,000.00 $
2014 6 778,216,000.00 $
2013 6 613,165,000.00 $


2016 6 125,300,000.00 $
2015 6 80,200,000.00 $
2014 6 176,225,000.00 $
2013 6 147,139,000.00 $
2012 6 112,151,000.00 $
2011 6 100,710,000.00 $
2010 6 152,303,000.00 $
2009 6 84,615,000.00 $
2008 6 47,845,000.00 $
2007 6 -34,962,000.00 $


2016 6 748,100,000.00 $
2015 6 662,100,000.00 $
2014 6 718,998,000.00 $
2013 6 728,594,000.00 $
2012 6 635,660,000.00 $

Shares Outstanding:

2016 6 72,400,000
2015 6 74,500,000
2014 6 78,182,000
2013 6 83,327,000
2012 6 86,465,000


Bloomberg News for MYRIAD GENETICS:

Feb 10, 2012
Nasdaq Short Interest as of Jan. 31
620 87,737 MYRX MYREXIS INC 171,102 212,920 27,673 MYGN MYRIAD GENETICS 2,889,711 2,829,144 719,834 NABI NABI BIOPHARMA...
Jun 30, 2008
H&R Block, Level 3, Wachovia, Whole Foods: U.S. Equity Movers
networks, saying lower valuations for telephone companies may hurt the stock. Myriad Genetics Inc. (MYGN US) fell the most since Nov. 7, losing 5.1 percent to $45.50. The biotech company's Alzheimer's...
Jun 30, 2008
Movers: NDS Group, H&R Block, France Telecom, Mesa Air, Del Monte
5 million in second quarter and $5 million in the second half of 2008. Myriad Genetics (MYGN) reports of the Act-Earli-AD trial, an 18-month Phase 3 study of Flurizan in patients with mild...
May 22, 2001
Reaping the Bush Dividend
one called Human Genome Sciences (HGSI ), and there's another one called Myriad Genetics (MYGN ). I'm not necessarily recommending those firms as the best ones to look at, but I'm saying...
Nov 17, 2003
Raising Forecast for Children's Place
estimate: .55 Rationale: See stronger operating income Company: Myriad Genetics (MYGN ) Year ending: Jun-2004 Prior estimate: -1.11 New estimate: -1.34 ...
Aug 26, 2003
CS First Boston Lowers Myriad Genetics to 'Neutral'
Credit Suisse First Boston downgraded Myriad Genetics (MYGN ) to neutral from outperform. Analyst Mark Augustine says...
Dec 14, 2006
S&P Ups Oracle to Strong Buy
reflecting a multiple reduction due to the aforementioned sales risks. Myriad Genetics (MYGN): Cuts to 3 STARS (hold) from 4 STARS (buy) Analyst: Paul Starsia Our downgrade comes...
Feb 7, 2005
Online Extra: Healthy Investment?
5.46 Prostate Cancer VIOLTS (FTPCSX) Myriad Genetics (MYGN) 10.07 Medarex (MEDX) ...
Dec 30, 2005
S&P's Top-Shelf Selections
of $135 billion for Procter & Gamble (PG ) to a low of $700 million for Myriad Genetics (MYGN ). By contrast, the median market capitalization of the S&P 500 index is about $10.3 billion...
Jun 22, 2007
Stocks: Eleven Cash-Flow Champs
14.83 Myriad Genetics (MYGN) 36.64 ...

Google News for MYRIAD GENETICS:

Nasdaq - 8 Dec 2017
Myriad Genetics (MYGN) Presents Positive riskScore Test Data
Myriad Genetics, Inc. MYGN presented encouraging data from a study to evaluate the risk of breast cancer in women of European lineage with a negative myRisk Hereditary Cancer test result for a hereditary cancer mutation. Notably, the results were presented at the 2017 San Antonio Breast Cancer ...
The Ledger Gazette
Myriad Genetics (MYGN) Reports Results From Two Important ...
Myriad Genetics, Inc. (NASDAQ: MYGN) today announced new results from two studies with EndoPredict® are being featured at the 2017 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. EndoPredict is a second-generation prognostic gene expression test for patients with breast ...
Analysts Opinion over Performance Valuation: Myriad Genetics, Inc ...
Myriad Genetics, Inc. (NASDAQ:MYGN) belongs to Services sector, other than individual factors many other macro and micro factors also effects whole sector and industries. Expecting these factors, the firm is standing on a contradictory position. To cut down amount of noise on price chart, shares of firm ...
BZ Weekly
Camber Capital Management Has Lowered By $33.13 Million Its ...
Camber Capital Management Llc decreased Myriad Genetics Inc (MYGN) stake by 30.64% reported in 2017Q2 SEC filing. Camber Capital Management Llc sold 1.33M shares as Myriad Genetics Inc (MYGN)'s stock rose 13.21%. The Camber Capital Management Llc holds 3.00M shares with $77.52M ...
StreetInsider.com - 10 Dec 2017
Here's how analysts see Myriad Genetics, Inc. (NASDAQ:MYGN ...
Investors sentiment decreased to 1.02 in Q2 2017. Its down 0.71, from 1.73 in 2017Q1. It dived, as 28 investors sold Myriad Genetics, Inc. shares while 74 reduced holdings. 45 funds opened positions while 59 raised stakes. 78.85 million shares or 1.67% less from 80.18 million shares in 2017Q1 were ...
The Ledger Gazette
Peeling Back the Layers on Shares of Myriad Genetics Inc (MYGN)
Shares of Myriad Genetics Inc (MYGN) are on watch as the Tenkan Line has moved above the Kijun line, indicating positive momentum for the equity. Myriad Genetics Inc moved 0.33 in the most recent session and touched 33.47 on a recent tick. The Tenkan Line or Tenkan Sen (Sen means line in ...
Leadership In Hereditary Cancer Testing Will Drive Myriad Genetics ...
Myriad Genetics (NASDAQ:MYGN) has been rapidly spreading its presence in the molecular diagnostics market. With 12 proprietary ... In this article, I plan to explain why I consider Myriad Genetics' robust hereditary cancer portfolio makes the company an exceptional long-term pick in calendar year 2017.
Market Monitor: Looking at Signals for Myriad Genetics Inc (MYGN)
Taking a look at opinion indicators for Myriad Genetics Inc (MYGN), we have noted that the signal is currently reading 40% Buy for the previous week. This is the combined signal for the last week using a variety of studies incorporating price movement. The opinion strength signal is currently reading Weak.
NASDAQ Times - 1 hour ago
Myriad Genetics Will Ride High On The Success Of Its New ...
In the previous article, I had explained why I believe Myriad Genetics's (NASDAQ:MYGN) Hereditary Cancer portfolio can prove to be a major growth driver for the company. This article will exclusively focus on the innovative product offerings from Myriad Genetics across therapeutic areas and the targeted ...
Key Gazette - 1 hour ago
Myriad Genetics Presents Results From Two Important EndoPredict ...
SALT LAKE CITY, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict® are being featured at the 2017 San Antonio Breast Cancer Symposium ...